Molecule Details
InChIKeyQDDQIPUKAXBMBX-UHFFFAOYSA-N
Compound NameCeralifimod
Canonical SMILESCCCc1ccc(COc2ccc3c(c2)CCC(CN2CC(C(=O)O)C2)=C3C)c(OC)c1
Clinical Status Data-mined Candidate
Targets (Human+Pathogen)3
Pfam Stratification Homologous
Avg pChEMBL8.66
SourceChEMBL;BindingDB
2D Structure
2D structure
Activity Profile
DrugBank Annotations
DrugBank ID DB16123
Drug NameCeralifimod
CAS Number891859-12-4
Groups investigational
ATC Codes nan
DescriptionCeralifimod is under investigation in clinical trial NCT01226745 (Phase 2 Extension Trial in Patients With Relapsing-remitting Multiple Sclerosis (RRMS)).
Categories: Azetines Immunologic Factors Immunosuppressive Agents Sphingosine 1 Phosphate Receptor Modulators
Cross-references: BindingDB: 50250631 CHEMBL4093489 ChemSpider: 9677798 RxCUI: 1846443 ZINC: ZINC000043130789
Target Activities (3)
Target Gene Organism Category Pfam pChEMBL Type Source
Q9H228 S1PR5 Homo sapiens Human PF00001 9.2 Ki ChEMBL;BindingDB
P21453 S1PR1 Homo sapiens Human PF00001 9.2 Ki ChEMBL;BindingDB
O95977 S1PR4 Homo sapiens Human PF00001 7.5 Ki ChEMBL;BindingDB
DrugBank Target Actions (1)
Target Gene Target Name Action Type
P21453 S1PR1 Sphingosine 1-phosphate receptor 1 agonist targets